<table>
<thead>
<tr>
<th>Title</th>
<th>Prenatal di(2-ethylhexyl) phthalate exposure and disruption of adrenal androgens and glucocorticoids levels in cord blood: The Hokkaido Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Araki, Atsuko; Mitsui, Takahiko; Goudarzi, Houman; Nakajima, Tamie; Miyashita, Chihiro; Itoh, Sachiko; Sasaki, Seiko; Cho, Kazutoshi; Moriya, Kimihiko; Shinohara, Nobuo; Nonomura, Katsuya; Kishi, Reiko</td>
</tr>
<tr>
<td>Citation</td>
<td>Science of The Total Environment, 581-582, 297-304</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2017-03-01</td>
</tr>
<tr>
<td>Doc URL</td>
<td><a href="http://hdl.handle.net/2115/72738">http://hdl.handle.net/2115/72738</a></td>
</tr>
<tr>
<td>Rights</td>
<td>© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license</td>
</tr>
<tr>
<td>Rights(URL)</td>
<td><a href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</a></td>
</tr>
<tr>
<td>Type</td>
<td>article (author version)</td>
</tr>
<tr>
<td>Additional Information</td>
<td>There are other files related to this item in HUSCAP. Check the above URL.</td>
</tr>
<tr>
<td>File Information</td>
<td>Araki_et_al_STOTEN2017.pdf</td>
</tr>
</tbody>
</table>

Hokkaido University Collection of Scholarly and Academic Papers : HUSCAP
Prenatal di(2-ethylhexyl) phthalate exposure and disruption of adrenal androgens and glucocorticoids levels in cord blood: The Hokkaido Study

Atsuko Araki¹, Takahiko Mitsui²,³, Houman Goudarzi¹,⁴, Tamie Nakajima⁵,⁶, Chihiro Miyashita¹,
Sachiko Itoh¹, Seiko Sasaki⁷, Kazutoshi Cho⁸, Kimihiko Moriya⁹, Nobuo Shinohara⁹, Katsuya Nonomura⁹,¹⁰, and Reiko Kishi¹

¹Center for Environmental and Health Sciences, Hokkaido University, Kita 12, Nishi 7, Sapporo, Hokkaido, Japan
²Department of Urology, Hokkaido University Hospital, Kita 15, Nishi 7, Sapporo, Hokkaido, Japan
³Yamanashi University, 1110, Shimogato, Chuo, Yamanashi, Japan
⁴Division of Respiratory Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Sapporo, Hokkaido, Japan
⁵Graduate School of Medicine, Nagoya University, Furo-cho, Chikusa-ku, Nagoya, Aichi, Japan
⁶College of Life and Health Sciences, Chubu University, 1200 Matsumoto-cho, Kasugai, Aichi, Japan
⁷Department of Public Health, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Sapporo, Hokkaido, Japan
⁸Department of Obstetrics and Gynecology, Hokkaido University Hospital, Kita 15, Nishi 7, Sapporo, Hokkaido, Japan
⁹Department of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido University,
20 Kita 15, Nishi 7, Sapporo, Hokkaido, Japan

21 10Kushiro Rosai Hospital, 13-23, Nakazono-cho, Kushiro, Hokkaido, Japan

22

23 Corresponding Author:

24 Reiko Kishi, MD, PhD, MPH

25 Center for Environmental and Health Sciences,

26 Hokkaido University,

27 Kita 12, Nishi 7, Kita-ku, Sapporo, Hokkaido 060-0812, Japan

28 Phone: +81-11-706-4746

29 Fax: +81-11-706-4725

30 E-mail: rkishi@med.hokudai.ac.jp

31

32

33 Disclosure Statement: The authors have nothing to disclose.
Abstract

Di(2-ethylhexyl) phthalate (DEHP) is known for its endocrine disrupting properties. We previously demonstrated that prenatal DEHP exposure is associated with decreased progesterone levels and testosterone/estradiol ratio in the cord blood. However, evidence of the effects of prenatal DEHP exposure on adrenal androgen and glucocorticoids in infants is scarce. Thus, the objectives of this study were to investigate the association between prenatal DEHP exposure and adrenal androgen and glucocorticoids, and to discuss its effects on steroid hormone profiles in infants. This is part of a birth cohort study: The Hokkaido Study on Environment and Children’s Health, Sapporo Cohort. Among the 514 participants, 202 mother-infant pairs with available data on maternal mono(2-ethylhexyl) phthalate (MEHP), adrenal androgen (dehydroepiandrosterone [DHEA] and androstenedione) and glucocorticoid (cortisol and cortisone) cord blood levels were included in this study. After adjusting for potential confounders, a linear regression analysis showed that maternal MEHP levels were associated with reduced cortisol and cortisone levels and glucocorticoid/adrenal androgen ratio, whereas increased DHEA levels and DHEA/androstenedione ratio. In a quartile model, when comparing the adjusted least square means in the 4th quartile of MEHP with those in the 1st quartile, cortisol and cortisone levels and glucocorticoid/adrenal androgen ratio decreased, whereas DHEA/androstenedione and cortisol/cortisone ratios increased. Significant p-value trends for cortisol and cortisone levels, cortisol/cortisone ratio, and glucocorticoid/adrenal androgen ratio were observed. In combination with the previous results of reduced progesterone levels and testosterone/estradiol
ratio, prenatal exposure to DEHP altered the steroid hormone profiles of infants. Further studies investigating the long-term effects of DEHP exposure on growth, neurodevelopment, and gonad and reproductive function are required.

**Key Words:** Di(2-ethylhexyl) phthalate (DEHP); mono(2-ethylhexyl) phthalate (MEHP); adrenal androgen; glucocorticoid; prenatal exposure; fetal blood

**Abbreviations:**

- CI, confidence interval
- CYP11A1, cytochrome P450 family 11 subfamily A member 1
- CYP11B1, cytochrome P450 family 11 subfamily B member 1
- CYP17A1, cytochrome P450 family 17 subfamily A member 1
- CYP19A1, cytochrome P450 family 19 subfamily A member 1
- CYP21A2, cytochrome P450 family 21 subfamily A member 2
- CV, coefficient of variation
- DBP, dibuthyl phthalate
- DEHP, di(2-ethylhexyl) phthalate
- DHEA, dehydroepiandrosterone
DHEA-S, DHEA sulfate

HSD11B2, hydroxysteroid 11-beta dehydrogenase 2

HSD17B1, hydroxysteroid 17-beta dehydrogenase 1

HSD3B1, hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1

IQR, interquartile range

LSM, least square means

MEHP, mono(2-ethylhexyl) phthalate

PFOS, perfluorooctane sulfonate

MBP, Monobutyl phthalate

PPAR, peroxisome proliferator-activated receptor

SULT2A1, DHEA sulfotransferase family 2A member 1

T/E2, testosterone/estradiol
Introduction

Phthalate diesters (phthalates) have been used as plasticizers for various plastic products, including toys, food containers, furniture, personal care products, medical devices, and housing materials. According to a report from the Japan Plasticizer Industry Association and Ministry of Economy, Trade and Industry in 2012, di(2-ethylhexyl) phthalate (DEHP) constitutes >50% of the phthalates used in production in Japan. Phthalates are not chemically bonded to polyvinyl chloride in plastic products; thus, they can leach into the air, dust, foodstuffs, and other materials. Consequently, humans are constantly exposed to phthalates, and biomonitoring studies have demonstrated the widespread exposure of the general population to these chemicals (Ait Bamai et al., 2015; Fromme et al., 2007; Jensen et al., 2015; Koch et al., 2004; Wittassek et al., 2007).

DEHP is a potential endocrine-disrupting chemical, and multiple adverse effects on human health due to DEHP exposure in early life were found. Phthalate exposure has been reported to shorten the anogenital distance of infants (Bornehag et al., 2015; Swan et al., 2005; Swan et al., 2015). The associations between phthalates exposure and neurodevelopment and childhood obesity were also investigated (Ejaredar et al., 2015; Kim and Park, 2014). The underlying mechanisms of their effects were not clearly understood; however, disruption of steroidogenesis could be one of the contributing factors because steroid hormones play an important role in homeostasis. Sex steroid hormones including testosterone, progesterone, and estradiol, have effects predominantly in the gonads; and dehydroepiandrosterone (DHEA) and androstenedione, which are weak adrenal steroid precursors, are
activated to form androgens and estrogens that have important roles in sex differentiation and maturation (Labrie et al., 2001). Glucocorticoids, including cortisol, and cortisone are synthesized within the adrenal cortex, and are involved in a wide range of physiological processes. Glucocorticoids are essential for regulating and/or modulating homeostasis in metabolism, growth, neurodevelopment, and the immune system (Braun et al., 2013; Reynolds, 2010). As a whole, steroid hormones in early life play important roles in reproductive growth and neurodevelopment for later life (Hollier et al., 2014; Quinn et al., 2016).

In previous experimental studies in rat, Chinese rare minnow, and zebrafish, DEHP and/or its primary metabolite, mono (2-ethylhexyl) phthalate (MEHP), were reported to upregulate and/or downregulate several enzymes in the steroidogenesis pathway (Akingbemi et al., 2001, 2004; Lehmann et al., 2004; Sekaran and Jagadeesan, 2015; Thompson et al., 2005; Zhu et al., 2016a; Zhu et al., 2016b). Exposure to DEHP could modify steroidogenesis and disrupt both hypothalamic-pituitary-gonad and hypothalamic-pituitary-adrenal axes. One animal study demonstrate that dibythol phthalate initiated a rapid and dynamic change in gene expression unique to the fetal testis while in the adrenal was unaffected (Thompson et al., 2005). However, there are fundamental regulation differences of steroidogenesis in the fetal testis between rodent and human (Scott et al., 2009). In addition to species differences, exposure timing, duration, and dosage variations between studies are not relevant for the human exposure scenario. Thus, results from animal studies are limited in predicting the impact of phthalates exposure on adrenal steroid
Despite the importance of DEHP properties on steroidogenesis, epidemiological studies on DEHP exposure, especially during early life, and its effects on adrenal androgen and glucocorticoid modulation are limited. In birth cohort studies in Mexico, the DHEA sulfate (DHEA-S) levels were increased and decreased following prenatal phthalate exposure in pubescent boys and girls, respectively (Ferguson et al., 2014; Watkins et al., 2014). In a Danish cohort, urinary phthalate metabolites in children were measured every 6 months from the baseline (aged 5.9 years) to pubertal age; girls with levels of monobutyl phthalate (MBP) and DEHP metabolites that were above the geometric group mean had lower levels of DHEA-S and androstenedione, whereas boys with higher MBP levels had lower DHEA-S levels (Mouritsen et al., 2013). Currently, only one study has investigated the effects of phthalate exposure on androstenedione and glucocorticoid levels in amniotic fluid, and the authors did not identify a significant association between phthalate and steroid hormone levels, including glucocorticoids (Jensen et al., 2015).

We recently demonstrated that prenatal DEHP exposure resulted in reduced progesterone levels and a reduced testosterone/estradiol (T/E2) ratio in cord blood (Araki et al., 2014). The aims of this study were to examine the effects of prenatal DEHP exposure on adrenal androgens (DHEA and androstenedione) and glucocorticoids (cortisol and cortisone), and to discuss its effects on the steroid hormone profile of infants, including adrenal androgens and glucocorticoids, and sex hormones (progesterone, testosterone, and estradiol) as reported by Araki et al. (2014).
Methods

Participants

This study was based on the Sapporo Cohort of the Hokkaido Study on Environment and Children’s Health. Details of this study, regarding the population, data collection, sampling of the biological specimens, and contents of the questionnaire, have been previously described (Kishi et al., 2013; Kishi et al., 2011). Briefly, native Japanese women at an obstetrics and gynecology hospital in Sapporo (Hokkaido, Japan), who lived in Sapporo City or surrounding areas, were enrolled in the study at 23–35 weeks of gestation between July 2002 and October 2005. Among the 1796 pregnant women approached, 25% were excluded as they were enrolled in the Japanese Cord Blood Bank or planned to deliver the baby at another hospital. Eventually, 514 pregnant women (28.6%) were enrolled in this study. Selection of participants included in the analysis was described in our previous study (Araki et al., 2014). Briefly, of the 514 participants, 10 were excluded from the study due to miscarriage, stillbirth, relocation, or voluntary withdrawal prior to delivery. A total of 493 maternal blood samples were available for MEHP measurements. However, maternal blood samples collected during hospitalization after delivery were excluded from this analysis due to the relatively short biological half-life of DEHP. Steroid hormone measurements were available for 295 infant cord blood samples. Finally, 202 samples with available MEHP and steroid hormone levels were included in the statistical analysis.
MEHP measurement

Maternal blood samples were obtained at the time of their hospital examination following recruitment. If a blood sample could not be taken during pregnancy due to maternal anemia, a blood sample was collected during hospitalization, within a week after delivery. All samples were stored at −80 °C until analysis. MEHP, which is the primary metabolite of DEHP, was measured by gas chromatography-mass spectrometry at Nagoya University. The methods for the preparation of samples and standard solutions, and the instrumental analysis have been described previously (Araki et al., 2014; Jia et al., 2015). The detection limit was 0.278 ng/mL (1 pmol/mL). MEHP levels in a tube containing the same medium as the reaction vial were measured to determine background levels. To exclude the possibility of environmental contamination of DEHP, glassware used for MEHP measurements was heated at 200 °C for 2 h. A total of 493 maternal blood samples were analyzed for MEHP levels. The coefficient of variation (CV) of MEHP measurements taken within a single day was 2.0%–7.8% for 6 days, and the day-to-day CV for 6 days was 6.2%, at 5 pmol/mL of concentration, as described previously (Jia et al., 2015).

Measurement of steroid hormones

At the time of delivery, a blood sample was collected from the umbilical cord and stored at −80 °C
Cord blood samples were available only from the children born vaginally. The concentrations of adrenal androgens and glucocorticoids were measured using liquid chromatography–tandem mass spectrometry (LC-MS/MS; Aska Pharma Medical Co., Ltd., Kanagawa, Japan). The methods for the preparation of samples, standard solutions, and instrumental analysis were described previously (Yamashita et al., 2007a; Yamashita et al., 2007b). The mean intra-assay CVs for steroid hormone measurements were as follows: DHEA, 2.1%–5.2%; androstenedione, 2.3%–6.8%; cortisol, 3.9%–10.9%; and cortisone, 1.3%–9.9%. The mean inter-assay CVs for steroid hormones were: DHEA, 3.3%–4.6%; androstenedione, 6.6%–7.1%; cortisol, 7.6%–11.3%; and cortisone: 7.8%–9.3% (Mitsui et al., 2016; Mitsui et al., 2015).

**Questionnaire and medical record**

The participants completed a self-administered questionnaire regarding information on maternal age, education level, household income, smoking and alcohol consumption during the first trimester, and medical history. Medical records were obtained at delivery for information regarding pre-pregnancy body mass index, pregnancy complications, parity, gestational age, infant sex, infant size, Apgar score, and congenital anomalies, including hypospadias and cryptorchidism.

**Statistical analyses**

Distribution of adrenal androgen and glucocorticoid levels among boys and girls were
compared using the Mann-Whitney U test. Associations between maternal MEHP concentrations and infant adrenal androgen and glucocorticoid levels were initially calculated using the Spearman’s rank correlation coefficient, followed by multivariate linear regression analysis. MEHP levels and adrenal androgen and glucocorticoid concentrations were converted to a log10 scale because they did not fall into a normal distribution. To evaluate whether the association between hormone and MEHP levels differed between sexes, a multivariate linear regression model for all study participants was first constructed with the interaction terms of hormone levels to sex and MEHP interaction. Since the MEHP and sex interaction was not significant for any of the hormones ($P_{\text{interaction}} > 0.05$), a further analysis was performed, in which both sexes were included in the same model. The interquartile range (IQR) for MEHP concentrations and the least square means (LSM) and 95% confidence intervals (CIs) for hormone levels were calculated. To calculate a p-value for the trend, linear contrast coefficients of -3, -1, +1, and +3 were assigned to 1st, 2nd, 3rd, and 4th quartiles, respectively (Goudarzi et al., 2016; Itoh et al., 2016). The 1st quartile was compared to the 2nd, 3rd, and 4th quartile MEHP, and the p-values were adjusted using the Bonferroni correction. When the levels were below the detection limits, half of their values were used for individual hormones. Inclusion of covariates was based on biological considerations, and included maternal age (continuous), maternal smoking during pregnancy (yes or no), maternal alcohol consumption during pregnancy (yes or no), gestational age (continuous), the week of gestation at which blood samples were taken (continuous), infant sex (boy or girl), and Apgar score (ordinal variable). A previous report from our cohort population
demonstrated that prenatal perfluorooctane sulfonate (PFOS) levels were associated with steroid hormone levels (Goudarzi et al., 2016; Itoh et al., 2016). Therefore, PFOS was also included in the adjusted model. All statistical analyses were performed using JMP Clinical 5.0 software (SAS Institute Inc., NC, USA).

Ethical approval

This study was approved by the Institutional Ethical Review Board for Epidemiological Studies at Hokkaido University Graduate School of Medicine, Hokkaido University Center for Environmental and Health Sciences, and Nagoya University Graduate School of Medicine, in accordance with the principles of the Declaration of Helsinki. All participants provided written informed consents.

Results

The characteristics of the participants included in this study are shown in Supplemental Table S1. Briefly, mean ± standard deviation maternal age at delivery (years) was 29.8 ± 4.9, and 54.5% were primiparous. For infants, the proportion of the boys was 46.0%, mean gestational age was 39.5 ± 1.0 weeks, and birth weight was 3138.6 ± 331.3 g. Apgar score at one minute after birth was nine for 82.7% children. Concentrations of MEHP in all samples were above the detection limit, and the median (IQR) concentration was 10.4 ng/mL (5.88–15.3 ng/mL). The concentration of MEHP was not significantly associated with any maternal or infant characteristics.
The adrenal androgen and glucocorticoid levels in infants are shown in Table 1. DHEA levels were significantly higher in girls than in boys. Correlations between MEHP levels and adrenal androgen and glucocorticoid concentrations are shown in Table 2, and the results of the linear regression after adjusting for potential confounders are shown in Table 3. MEHP levels were inversely associated with cortisol and cortisone levels and glucocorticoid/adrenal androgen ratio, but positively associated with DHEA levels and DHEA/androstenedione ratios.

The associations between MEHP and adrenal androgen and cortisol levels were analyzed for potential non-linear relationships. The LSM for each hormone in each MEHP quartile is shown in Figure 1, with details of the data in Supplemental Table S2. The adjusted LSM adrenal androgen and cortisol levels in relation to the MEHP quartile showed a significant p-value trend for cortisol and cortisone levels, cortisol/cortisone ratio, and glucocorticoid/adrenal androgen ratio. When comparing the LSM in the 4th quartile of MEHP with those in the 1st quartile, cortisol and cortisone concentrations and glucocorticoid/adrenal androgen ratio were decreased, whereas DHEA/androstenedione and cortisol/cortisone ratios were increased.

Since there were significant differences in DHEA levels in the cord blood with respect to sex, the associations between MEHP levels and DHEA concentrations were examined separately in boys and girls for both, linear and quartile models. However, there was no association found between MEHP and DHEA levels in either boys or girls (data not shown).
Discussion

We have investigated the associations between maternal MEHP levels and cord blood adrenal androgens (DHEA and androstenedione) and glucocorticoids (cortisol and cortisone) in mother-infant pairs of a prospective birth cohort. Our results demonstrated a significant association between increased maternal MEHP levels and decreased levels of cortisol and cortisone levels and glucocorticoid/adrenal androgen ratio, and increased DHEA/androstenedione ratio in linear models. In quartile models, p-values for trends were statistically significant for cortisol and cortisone levels, and cortisol/cortisone and glucocorticoid/adrenal/androgen ratios. However, in the 4th quartile of MEHP, cortisol and cortisone levels, glucocorticoid/adrenal androgen ratio were significantly lower, and DHEA/androstenedione and cortisol/cortisone ratios were significantly higher compared with the 1st quartile of MEHP. We have previously reported that increased maternal MEHP levels decreased progesterone levels and testosterone/estradiol (T/E2) ratio in the cord blood (Araki et al., 2014). In combination, the study provided novel evidence regarding the effects of prenatal DEHP exposure on steroidogenesis disruption in infants, and a threshold for such effects was found.

In previous studies, we demonstrated that PFOS levels were inversely associated with progesterone, T/E2 ratio, cortisol, and cortisone, and positively associated with DHEA (Goudarzi et al., 2016; Itoh et al., 2016). Nuclear receptors, including peroxisome proliferator-activated receptor (PPAR) alpha and gamma, are essential regulators of steroidogenesis, and both PFOS and DEHP are known ligands of these receptors (Lovekamp-Swan et al., 2003; Vanden Heuvel et al., 2006). Thus,
the effects of PFOS and DEHP exposure on steroidogenesis could overlap. In addition, there was a statistically significance correlation between PFOS and MEHP (Spearman’s rho = 0.453, P < 0.001).

Therefore, we performed a mutual adjustment with PFOS so that the changes of steroid hormone levels by MEHP in this study were independent of the effect of PFOS. For further assessment, as an indicator of infant stress at birth, we have included the Apgar score (one minute after birth, ordinal variable) into the adjusted model and the results remained consistent (Supplemental Table S3).

Therefore, stress of the birth process cannot be a confounder in our study.

Previous studies examining the effects of exposure to DEHP on adrenal androgen and glucocorticoids in humans are limited. A Danish pregnancy-screening biobank study, which consisted of cases of cryptorchidism and hypospadias and control boys, reported that increased levels of mono (2-ethyl-5-carboxypentyl) phthalate, another metabolite of DEHP, was associated with higher levels of androstenedione and cortisol in the second trimester amniotic fluid (Jensen et al., 2015). Further, a statistically significant association between DEHP metabolites and hormones seemed more strongly in cases than controls (Jensen et al., 2015). However, increased MEHP levels in the present study were associated with reduced androstenedione and cortisol levels, although the p-values did not reach statistically significant levels. Steroid hormone levels shift during the gestational period, such that the inconsistent results could be due to the timing of the steroid measurements (Kuijper et al., 2013). In addition, there were no cases of cryptorchidism or hypospadias in present study. Thus, difference of the study participants could be another reason for the inconsistencies of the results.
This is the first study that examined MEHP exposure and DHEA levels at birth, and reported that MEHP levels were inversely associated with DHEA levels in a linear model. In birth cohort studies in Mexico, DHEA-S levels were increased and decreased in pubescent boys and girls, respectively, following prenatal phthalate exposure (Ferguson et al., 2014; Watkins et al., 2014). Mouristen et al. (2013) reported the results of a prospective cohort study in Denmark, in which phthalate levels in the urine of children were inversely associated with the DHEA-S levels in both sexes (Mouritsen et al., 2013). These studies in Mexico and Denmark measured hormone levels in children at puberty, whereas the present study measured hormones at birth. Another explanation for the inconsistencies between the results of this study and those of previous studies is that DHEA-S, instead of DHEA, was measured in the Mexico and Denmark studies. The levels of a DHEA sulfotransferase family 2A member 1 (SULT2A1), which converts DHEA to DHEA-S, were reported to be downregulated by phthalates in a previous study (Harris et al., 2007). Therefore, the effects of DEHP exposure on the levels of DHEA and DHEA-S could differ.

The findings of this study could be explained by previous experimental studies as shown in Figure 2. Decreased levels of progesterone following DEHP exposure likely resulted from the downregulation of hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 (HSD3B1). Similarly, increases in the DHEA levels and DHEA/androstenedione ratio could also result from the downregulation of HSD3B1. Increased cortisol/cortisone ratios could be due to DEHP-mediated downregulation of hydroxysteroid 11-beta dehydrogenase 2 (HSD11B2). Finally,
decreased levels of cortisol and cortisone, together with a reduced glucocorticoid/adrenal androgen ratio, could be due to a shift of steroidogenesis from glucocorticoids to adrenal androgen by downregulation of HSD3B1 and hydroxysteroid 17-beta dehydrogenase 1 (HSD17B1). Additionally, cholesterol is a substrate of whole steroid hormones. Thus, changes in the cholesterol profile following exposure to DEHP may exist as demonstrated in a previous study of elderly patients in which reduced levels of cholesterol were detected following DEHP exposure (Olsén et al., 2012).

Previous animal and in vitro studies have provided evidence that phthalates, including DEHP and/or MEHP, modify the expression of genes encoding steroidogenesis enzymes. MEHP exposure decreased HSD11B2, cytochrome P450 family 11 subfamily A member 1 (CYP11A1), HSD3B1, and HSD17B1 (Akingbemi et al., 2001; Hong et al., 2009; Lehmann et al., 2004; Sekaran and Jagadeesan, 2015; Thompson et al., 2005; Zhao et al., 2010; Zhu et al., 2016a; Zhu et al., 2016b). Although one experimental study suggested upregulation of CYP17A1 (Wang et al., 2013), other studies found DEHP and/or MEHP exposure induced inhibition of cytochrome P450 family 17 subfamily A member 1 (CYP17A1) (Akingbemi et al., 2001; Chauvigne et al., 2011; Lehmann et al., 2004). Thus, increased levels of DHEA in this study may be better explained by inhibition of SULT2A1, HSD3B1, and HSD17B1 than activation of CYP17A1. As for cytochrome P450 family 19 subfamily A member 1 (CYP19A1), Wang et al. suggested that direction of up/downregulation differ between sex (Wang et al., 2013). Nevertheless, many of the in vitro and animal studies were conducted with concentrations and doses that are not relevant for the human exposure scenario. Moreover, the changes in gene
expression of steroidogenic enzymes may vary significantly depending on the experimental conditions, such as cell lines, species, doses, timing, and duration of exposure. (Akingbemini et al., 2001, 2004; Ge et al., 2007).

As we described in our previous study (Araki et al., 2014), the levels of MEHP in this cohort were slightly higher than those in American adults (NHANES 1999–2000), elderly Swedish subjects, and pregnant women in Australia (Hart et al., 2014; Lind et al., 2012; Silva et al., 2004). Slightly higher MEHP levels in this study can be considered acceptable as the levels of DEHP in house dust in Sapporo, Japan were higher compared with the studies from other countries, and DEHP intake in the Japanese population was higher than that of most other studies (Ait Bamai et al., 2014; Ait Bamai et al., 2015). On the other hand, as for the first limitation, it should be also noted that MEHP in blood was measured as urine samples were not available in this study. All samples were handled carefully to avoid ex vivo hydrolysis of DEHP; therefore, measurement errors due to contamination were minimal (Araki et al., 2014). Nevertheless, mono (2-ethyl-5-carboxypentyl) phthalate and mono (2-ethyl-5-hydroxyhexyl) phthalate have previously been detected in maternal serum (Hart et al., 2014); thus, these secondary metabolites should be measured in future studies.

Another limitation of this study was that the MEHP level was measured only once from second to third trimester. However, although there are contradicting discussions regarding this in the literature, several previous reports have found that single measurements can be useful (Hoppin et al., 2002; Townsend et al., 2013). In addition, the blood sampling week was adjusted to minimize the
effect of timing of exposure in this study. Although, we cannot rule out a possibility of the effect from acute exposure before delivery at the hospital, non-differential errors bias an effect towards the null.

In this study, all participants who delivered vaginally with available cord blood samples were included in the analysis. Compared to the initial cohort population, the infants had an increased gestational age and heavier birth weight than those who were excluded from the study. As a result, healthier infants were included in the analysis; thus, the effects of MEHP may be underestimated in this study. In addition, the participation rate in our cohort study is rather low, which may limit the extrapolation of our results to the general population. Finally, the observation of only minimal reductions in the levels of cortisol in the linear model ($0.1 > P > 0.05$) may have been due to the limited sample size. Future studies with larger sample sizes are then required to confirm the results. A major strength of the present study is that this has a prospective birth cohort design, in which the effects of prenatal DEHP exposure on fetal adrenal androgen and glucocorticoids could be estimated. In addition, steroid hormones were measured by LC-MS/MS methods, which are considered more accurate than other methods, such as radioimmunoassay.

**Conclusion**

In summary, this study found significant associations between increased maternal MEHP levels and reduced cortisol and cortisone levels and glucocorticoid/adrenal androgen ratio and increased DHEA/androstenedione and cortisol/cortisone ratios. In combination with the previous results of
reduced progesterone levels (Araki et al., 2014), the present results suggested that prenatal DEHP exposure disrupted the steroid hormone profile of infants, despite the levels of DEHP in the general population being markedly lower than those in experimental studies. Disrupting the balance of steroid hormones may cause adverse effects on reproductive growth, development, and other health outcomes in later life. The clinical significance of these findings is unclear at present because it remains unknown whether these small hormonal alterations exert any effect on health.

Acknowledgements

We would like to thank the mothers and children that participated in the study and the staff at the Sapporo Toho Hospital. This study was supported in part by the Japan Ministry of Health, Labour and Welfare; the Environment Research and Technology Development Fund (5C-1252 and 5-2554); and Grants in Aid of Scientific Research from the Japan Society for the Promotion of Science, the Ministry of Education, Culture, Sports, Science and Technology (13307015, 16209022, 19209024, 22249021, 26740028, and 26670321).
References


Lind, P.M.; Roos, V.; Ronn, M.; Johansson, L.; Ahlstrom, H.; Kullberg, J.; Lind, L. Serum concentrations of phthalate metabolites are related to abdominal fat distribution two years later in elderly women. Environ Health 2012;11:21

Lovekamp-Swan, T.; Jetten, A.M.; Davis, B.J. Dual activation of PPARα and PPARγ by mono-(2-ethylhexyl) phthalate in rat ovarian granulosa cells. Mol Cell Endocrinol 2003;201:133-141


Quinn, T.A.; Ratnayake, U.; Dickinson, H.; Castillo-Melendez, M.; Walker, D.W. The feto-placental
unit, and potential roles of dehydroepiandrosterone (DHEA) in prenatal and postnatal brain development: a re-examination using the spiny mouse. J Steroid Biochem Mol Biol 2016;160:204-213


Table 1. Distribution of adrenal androgen and glucocorticoid concentrations

<table>
<thead>
<tr>
<th></th>
<th>Detection limit</th>
<th>&gt;Detection limit (%)</th>
<th>Total (n = 202) Med (IQR)</th>
<th>Boys (n = 93) Med (IQR)</th>
<th>Girls (n = 109) Med (IQR)</th>
<th>^p-value</th>
</tr>
</thead>
</table>
| **Adren
al androgen** |                 |                      |                           |                         |                          |          |
| DHEA (ng/mL)         | 0.010           | 100                  | 2.31 (1.79, 3.07)         | 2.08 (1.59, 2.71)       | 2.62 (1.99, 3.42)        | <0.001   |
| Androstenedione (ng/mL) | 0.010      | 100                  | 0.46 (0.36, 0.58)         | 0.47 (0.38, 0.59)       | 0.45 (0.35, 0.58)        | 0.572    |
| **Glucocorticoid**   |                 |                      |                           |                         |                          |          |
| Cortisol (ng/mL)     | 0.250           | 96.5                 | 40.5 (22.7, 66.7)         | 41.1 (22.3, 66.8)       | 39.3 (24.1, 66.8)        | 0.902    |
| Cortisone (ng/mL)    | 0.100           | 93.6                 | 96.9 (70.3, 124)          | 97.2 (72.5, 126)        | 96.0 (69.2, 125)         | 0.734    |

DHEA, dehydroepiandrosterone; IQR, the interquartile range

^p-values were calculated by Mann-Whitney U test comparing boys and girls
### Table 2. Associations between MEHP and hormone levels

<table>
<thead>
<tr>
<th></th>
<th>$^a\rho$</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>DHEA</td>
<td>0.136</td>
<td>0.054</td>
</tr>
<tr>
<td>Androstenedione</td>
<td>-0.190</td>
<td>0.007</td>
</tr>
<tr>
<td>DHEA/androstenedione</td>
<td>0.178</td>
<td>0.011</td>
</tr>
<tr>
<td>Androstenedione/testosterone</td>
<td>0.027</td>
<td>0.699</td>
</tr>
<tr>
<td>Cortisol</td>
<td>-0.273</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Cortisone</td>
<td>-0.367</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Cortisol/cortisone</td>
<td>0.038</td>
<td>0.592</td>
</tr>
<tr>
<td>Glucocorticoid/adrenal androgen</td>
<td>-0.297</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

$^a$Spearman's $\rho$

MEHP, mono(2-ethylhexyl)phthalate; DHEA, dehydroepiandrosterone
Table 3. Adjusted linear regression coefficients of adrenal androgen and glucocorticoid in the cord blood in relation to MEHP

<table>
<thead>
<tr>
<th>Steroid hormone levels</th>
<th>Crude model</th>
<th>Adjusted model</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β (95% CI)</td>
<td>p-value</td>
</tr>
<tr>
<td>DHEA</td>
<td>0.246 (0.095, 0.397)</td>
<td>0.002</td>
</tr>
<tr>
<td>Androstenedione</td>
<td>-0.079 (-0.199, 0.042)</td>
<td>0.198</td>
</tr>
<tr>
<td>DHEA/androstenedione</td>
<td>0.325 (0.147, 0.503)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Androstenedione/testosterone</td>
<td>0.002 (0.000, 0.003)</td>
<td>0.082</td>
</tr>
<tr>
<td>Cortisol</td>
<td>-0.527 (-0.809, -0.245)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cortisone</td>
<td>-0.734 (-1.111, -0.358)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cortisol/cortisone</td>
<td>0.207 (0.040, 0.375)</td>
<td>0.015</td>
</tr>
<tr>
<td>Glucocorticoid/adrenal</td>
<td>-0.828 (-1.258, -0.398)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Steroid hormone levels and MEHP concentrations were log10-transformed and included in the model separately.

- β for linear regression coefficients
- Adjusted for maternal age, smoking and alcohol consumption during pregnancy, gestational age, blood sampling week, infant sex, and PFOS
- 95%CI, 95% confidence interval; DHEA, dehydroepiandrosterone; MEHP, mono(2-ethylhexyl)phthalate; PFOS, perfluorooctane sulfonate levels,
Figure 1:

- **A** DHEA
  - P-value for trend = 0.143

- **B** DHEA/Androstenedionedione
  - P-value for trend = 0.053

- **C** Cortisol
  - P-value for trend = 0.016

- **D** Cortisone
  - P-value for trend = 0.021

- **E** Cortisol/Cortisone
  - P-value for trend = 0.036

- **F** Glucocorticoid/Adrenal androgen
  - P-value for trend = 0.030
Figure 2
**Figure legend**

Figure 1

X-axis shows the mono(2-ethylhexyl) phthalate (MEHP) quartiles, and Y-axis shows each hormone level. The adjusted least square means (LSMs) with 95% confidence intervals for each hormone in the cord blood in relation to the MEHP concentration quartile fit to all study participants are shown with a *p*-value trend for: (A) DHEA, (B) DHEA/androstenedione ratio, (C) cortisol, (D) cortisone, (E) cortisol/cortisone ratio, and (F) glucocorticoid (cortisol and cortisone)/adrenal androgen (DHEA and androstenedione) ratio. There was a significant and inverse association between MEHP levels and cortisol and cortisone levels, glucocorticoid/adrenal androgen ratio, but a positive association between MEHP levels and the cortisol/cortisone ratio. The 1st quartile (≤ 5.88 ng/mL) was compared with the 2nd (5.88–10.4 ng/mL), 3rd (10.4–15.3 ng/mL), and 4th (> 15.3 ng/mL) quartile MEHP levels. Statistical significance of the *P* values were *p* < 0.017 and **P** < 0.0033 based on Bonferroni correction. When compared with the LSM of the 1st MEHP quartile, the 4th MEHP quartile of cortisol, cortisone, and glucocorticoid/adrenal androgen ratios were significantly decreased, whereas the DHEA/androstenedione ratio and cortisol/cortisone ratio were significantly increased. LSMs were adjusted for maternal age, smoking and alcohol consumption during pregnancy, gestational age, blood sampling week, infant sex, and perfluorooctane sulfonate level.

Abbreviations: DHEA, dehydroepiandrosterone; LSM, least square means, MEHP, mono(2-ethylhexyl) phthalate.
Figure 2

Steroid metabolic pathways and their disruption following mono(2-ethylhexyl) phthalate (MEHP) exposure. Squares indicate the hormones measured in this study and our previous report. Black bold arrows indicate the direction of shift following MEHP exposure. Black characters and arrows in gray background and rounded rectangles indicate enzymes reported as upregulated or downregulated by di(2-ethylhexyl) phthalate (DEHP) and/or MEHP in experimental studies.

Abbreviations: CYP11A1, cytochrome P450 family 11 subfamily A member 1; CYP11B1, cytochrome P450 family 11 subfamily B member 1; CYP17A1, cytochrome P450 family 17 subfamily A member 1; CYP19A1, cytochrome P450 family 19 subfamily A member 1; CYP21A2, cytochrome P450 family 21 subfamily A member 2; HSD11B2, hydroxysteroid 11-beta dehydrogenase 2; HSD17B1, hydroxysteroid 17-beta dehydrogenase 1; HSD3B1, hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1; SULT2A1, DHEA sulfotransferase family 2A member 1